Skip to main content
SpringerLink
Log in

Clinical outcomes and factors involved in the local control of proton beam therapy for oligometastatic liver tumors in patients with colorectal cancer

  • Original Article
  • Published:
Strahlentherapie und Onkologie Aims and scope Submit manuscript

Abstract

Background and purpose

There are no existing reports on proton beam therapy (PBT) for local control (LC) of liver metastasis of colorectal cancer (LMCRC). We calculated the LC rate of PBT for LMCRC and explored the influence of each factor on the LC rate.

Materials and methods

Cases in which PBT was performed at our center between 2009 and 2018 were retrospectively selected from the database. Patients with LMCRC without extrahepatic lesions and no more than three liver metastases were included. Effectiveness was assessed based on LC, overall survival (OS), and progression-free survival (PFS) rates. Adverse events (AEs) are described. Factors that may be related to LC were also investigated.

Results

This study included 23 men and 18 women, with a median age of 66 (range 24–87) years. A total of 63 lesions were included in the study. The most frequent dose was 72.6 Gy (relative biological effectiveness)/22 fractions. The median follow-up period was 27.6 months. The 3‑year LC, OS, and PFS rates were 54.9%, 61.6%, and 16.7%, respectively. Our multivariate analysis identified the distance between the tumor and the gastrointestinal (GI) tract as a factor associated with LC (P = 0.02). No grade ≥ 3 AEs were observed. None of the patients experienced liver failure during the acute or late phase.

Conclusion

Care must be taken with tumors that have reduced planning target volume coverage owing to organs at risk restrictions, especially in tumors near the GI tract.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Mizumoto M, Oshiro Y, Okumura T et al (2016) Proton beam therapy for Hepatocellular carcinoma: a review of the university of Tsukuba. Experience Int J Part Ther 2:570–578. https://doi.org/10.14338/IJPT-15-00035.2

    Article  PubMed  Google Scholar 

  2. Fukumitsu N, Okumura T, Takizawa D et al (2015) Proton beam therapy for metastatic liver tumors. Radiother Oncol 117:322–327. https://doi.org/10.1016/J.RADONC.2015.09.011

    Article  PubMed  Google Scholar 

  3. Coffman AR, Sufficool DC, Kang JI et al (2021) Proton stereotactic body radiation therapy for liver metastases-results of 5‑year experience for 81 hepatic lesions. J Gastrointest Oncol 12:1753–1760. https://doi.org/10.21037/JGO-20-424

    Article  PubMed  PubMed Central  Google Scholar 

  4. Moyers MF, Miller DW, Bush DA, Slater JD (2001) Methodologies and tools for proton beam design for lung tumors. Int J Radiat Oncol Biol Phys 49:1429–1438. https://doi.org/10.1016/S0360-3016(00)01555-8

    Article  CAS  PubMed  Google Scholar 

  5. Schwartz LH, Litière S, de Vries E et al (2016) RECIST 1.1-Update and clarification: from the RECIST committee. Eur J Cancer 62:132–137. https://doi.org/10.1016/J.EJCA.2016.03.081

    Article  PubMed  PubMed Central  Google Scholar 

  6. Kanda Y (2013) Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant 48:452–458. https://doi.org/10.1038/BMT.2012.244

    Article  CAS  PubMed  Google Scholar 

  7. Yamaguchi H, Honda M, Hamada K et al (2020) The effectiveness of proton beam therapy for liver metastatic recurrence in gastric cancer patients. Jpn J Clin Oncol 50:903–908. https://doi.org/10.1093/JJCO/HYAA052

    Article  PubMed  Google Scholar 

  8. Fukumitsu N, Okumura T, Takizawa D et al (2017) Proton beam therapy for liver metastases from gastric cancer. J Radiat Res 58:357–362. https://doi.org/10.1093/JRR/RRW102

    Article  PubMed  Google Scholar 

  9. Fukumitsu N, Okumura T, Numajiri H et al (2017) Follow-up study of liver metastasis from breast cancer treated by proton beam therapy. Mol Clin Oncol 7:56–60. https://doi.org/10.3892/MCO.2017.1283

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Shiba S, Shibuya K, Okamoto M et al (2021) Carbon-ion radiotherapy for oligometastatic colorectal cancer in the liver or lung. Anticancer Res 41:1997–2005. https://doi.org/10.21873/ANTICANRES.14967

    Article  CAS  PubMed  Google Scholar 

  11. Ahmed KA, Caudell JJ, El-Haddad G et al (2016) Radiosensitivity differences between liver metastases based on primary histology suggest implications for clinical outcomes after stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 95:1399–1404. https://doi.org/10.1016/J.IJROBP.2016.03.050

    Article  PubMed  PubMed Central  Google Scholar 

  12. Chang DT, Swaminath A, Kozak M et al (2011) Stereotactic body radiotherapy for colorectal liver metastases: a pooled analysis. Cancer 117:4060–4069. https://doi.org/10.1002/CNCR.25997

    Article  PubMed  Google Scholar 

  13. Doi H, Uemoto K, Suzuki O et al (2017) Effect of primary tumor location and tumor size on the response to radiotherapy for liver metastases from colorectal cancer. Oncol Lett 14:453–460. https://doi.org/10.3892/OL.2017.6167

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Goodman BD, Mannina EM, Althouse SK et al (2016) Long-term safety and efficacy of stereotactic body radiation therapy for hepatic oligometastases. Pract Radiat Oncol 6:86–95. https://doi.org/10.1016/J.PRRO.2015.10.011

    Article  PubMed  Google Scholar 

  15. Hoyer M, Roed H, Hansen AT et al (2006) Phase II study on stereotactic body radiotherapy of colorectal metastases. Acta Oncol 45:823–830. https://doi.org/10.1080/02841860600904854

    Article  PubMed  Google Scholar 

  16. Three-fraction stereotactic body radiation therapy for isolated liver recurrence from colorectal cancer—PubMed. https://pubmed.ncbi.nlm.nih.gov/19856655/. Accessed 27 Mar 2022

  17. Liu E, Stenmark MH, Schipper MJ et al (2013) Stereotactic body radiation therapy for primary and metastatic liver tumors. Transl Oncol 6:442–446. https://doi.org/10.1593/TLO.12448

    Article  PubMed  PubMed Central  Google Scholar 

  18. McPartlin A, Swaminath A, Wang R et al (2017) Long-term outcomes of phase 1 and 2 studies of SBRT for hepatic colorectal metastases. Int J Radiat Oncol Biol Phys 99:388–395. https://doi.org/10.1016/J.IJROBP.2017.04.010

    Article  PubMed  Google Scholar 

  19. Méndez Romero A, Keskin-Cambay F, van Os RM et al (2017) Institutional experience in the treatment of colorectal liver metastases with stereotactic body radiation therapy. Rep Pract Oncol Radiother 22:126–131. https://doi.org/10.1016/J.RPOR.2016.10.003

    Article  PubMed  Google Scholar 

  20. Scorsetti M, Comito T, Tozzi A et al (2015) Final results of a phase II trial for stereotactic body radiation therapy for patients with inoperable liver metastases from colorectal cancer. J Cancer Res Clin Oncol 141:543–553. https://doi.org/10.1007/S00432-014-1833-X

    Article  CAS  PubMed  Google Scholar 

  21. Stintzing S, Grothe A, Hendrich S et al (2013) Percutaneous radiofrequency ablation (RFA) or robotic radiosurgery (RRS) for salvage treatment of colorectal liver metastases. Acta Oncol 52:971–977. https://doi.org/10.3109/0284186X.2013.766362

    Article  PubMed  Google Scholar 

  22. van der Pool AEM, Méndez RA, Wunderink W et al (2010) Stereotactic body radiation therapy for colorectal liver metastases. Br J Surg 97:377–382. https://doi.org/10.1002/BJS.6895

    Article  PubMed  Google Scholar 

  23. Petrelli F, Comito T, Barni S et al (2018) Stereotactic body radiotherapy for colorectal cancer liver metastases: A systematic review. Radiother Oncol 129:427–434. https://doi.org/10.1016/J.RADONC.2018.06.035

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

We would like to thank Editage (www.editage.com) for English language editing.

Funding

No external funding was received for conducting this study.

Author information

Authors and Affiliations

  1. Department of Minimally Invasive Surgical and Medical Oncology, Fukushima Medical University, 1 Hikarigaoka, 960-1295, Fukushima City, Fukushima, Japan

    Hisashi Yamaguchi M.D., Michitaka Honda Ph.D., Koichi Hamada M.D. & Yukitoshi Todate M.D.

  2. Department of Radiology, Southern Tohoku Proton Therapy Center, Koriyama City, Fukushima, Japan

    Hisashi Yamaguchi M.D., Takahiro Kato Ph.D., Ichiro Seto Ph.D., Takuya Tominaga D.D.S, Masanori Machida M.D., Yoshiaki Takagawa M.D., Kanako Takayama Ph.D., Motohisa Suzuki M.D., Yasuhiro Kikuchi Ph.D. & Masao Murakami Ph.D.

  3. Department of Surgery, Southern Tohoku General Hospital, Koriyama City, Fukushima, Japan

    Michitaka Honda Ph.D., Yukitoshi Todate M.D. & Yasushi Teranishi Ph.D.

  4. Department of Gastroenterology, Southern Tohoku General Hospital, Koriyama City, Fukushima, Japan

    Koichi Hamada M.D.

  5. Division of Radiology, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Sendai City, Miyagi, Japan

    Yojiro Ishikawa Ph.D.

  6. Department of Orthopaedic Surgery, Fukushima Medical University, Fukushima City, Fukushima, Japan

    Shinichi Konno Ph.D.

Authors
  1. Hisashi Yamaguchi M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Takahiro Kato Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michitaka Honda Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Koichi Hamada M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yukitoshi Todate M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yojiro Ishikawa Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ichiro Seto Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Takuya Tominaga D.D.S
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Masanori Machida M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Yoshiaki Takagawa M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Kanako Takayama Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Motohisa Suzuki M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Yasuhiro Kikuchi Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Yasushi Teranishi Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Masao Murakami Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Shinichi Konno Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors contributed to study conception and design. Material preparation, data collection, and analysis were performed by Hisashi Yamaguchi, Takahiro Kato, Michitaka Honda, and Shinichi Konno. The first draft of the manuscript was written by Hisashi Yamaguchi, and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Hisashi Yamaguchi M.D..

Ethics declarations

Conflict of interest

H. Yamaguchi, T. Kato, M. Honda, K. Hamada, Y. Todate, Y. Ishikawa, I. Seto, T. Tominaga, M. Machida, Y. Takagawa, K. Takayama, M. Suzuki, Y. Kikuchi, Y. Teranishi, M. Murakami, and S. Konno declare that they have no competing interests.

Additional information

Data availability statement

Research data are stored in an institutional repository and will be shared upon request to the corresponding author.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yamaguchi, H., Kato, T., Honda, M. et al. Clinical outcomes and factors involved in the local control of proton beam therapy for oligometastatic liver tumors in patients with colorectal cancer. Strahlenther Onkol 199, 304–312 (2023). https://doi.org/10.1007/s00066-022-02023-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00066-022-02023-z

Keywords

Search

Navigation